Last updated: May 26, 2026
Macitentan Suppliers: Who Manufactures, Licenses, and Supplies the Active Ingredient and Finished Dosage Forms?
Macitentan supply is concentrated around a small number of global active pharmaceutical ingredient (API) and finished-dose manufacturers supporting brand distribution and generic entry pathways. In practice, the supplier set splits into: (1) API manufacturers producing macitentan bulk drug substance, and (2) contract manufacturing organizations (CMOs) and finished-dose sites producing 10 mg and 50 mg tablets for distribution in major markets, often under supply agreements tied to patent and exclusivity constraints.
Who supplies macitentan API (active pharmaceutical ingredient) to drug manufacturers?
Macitentan API is typically supplied under commercial bulk supply and GMP release testing arrangements. For branded and authorized generic programs, the API supply chain generally runs through a limited set of qualified suppliers with proven regulatory history and validated polymorph control, impurity control, and solvent/residual specifications.
What macitentan API suppliers usually include
- API makers producing macitentan drug substance under cGMP with batch release for finished dosage manufacturers.
- Specialty intermediates suppliers producing key synthetic intermediates used in macitentan formation.
- Analytical testing labs supporting impurity profiling (process impurities, degradation products) required for batch disposition.
Supplier selection criteria for macitentan
- Powder handling and crystallization control (critical for impurity and polymorph stability).
- Scalable synthesis with controlled residual solvents.
- Ability to support ANDA/MAA comparability packages, where applicable.
Which companies supply macitentan tablets (10 mg and 50 mg finished dosage forms)?
Macitentan is marketed as a tablet (10 mg and 50 mg strengths). Finished-dose supply typically involves:
- Brand manufacturing or authorized manufacturing sites for the reference product.
- CMOs producing tablets for market distribution, including at launch and during authorized generic transitions.
- Distribution networks aligned to country-specific regulatory approvals.
Finished-dose supply model
- Marketing authorization holder sets finished-dose manufacturing specifications.
- Qualified tablet CMOs produce and package tablets.
- Site release and QA disposition occur before distribution.
Tablet manufacturing steps with supply leverage
- Granulation and compression process validation.
- Coating/film formulation, if applicable to the marketed dosage form.
- Packaging-line validation to prevent mix-ups across strengths.
What patent-expiration timing affects macitentan supplier options?
Macitentan supplier availability in the market is tightly coupled to:
- Brand exclusivity for the reference product.
- Patent estates covering polymorphs, process impurities, formulation details, and method-of-use claims.
- Regulatory exclusivity and data exclusivity that delay generic approvals and launches.
Impact on supplier landscape
- During exclusivity, finished-dose supply and API supply are typically limited to brand or authorized supply chains.
- After key exclusivity windows, more suppliers can qualify through: quality agreements, DMF bridging, and regulatory filing support.
How does Paragraph IV (ANDA) generic strategy change macitentan supplier risk?
Generic suppliers that pursue a Paragraph IV strategy depend on:
- Ability to secure macitentan API at commercial scale with compliance to listed impurities and stability criteria.
- Manufacturing process that avoids infringing process and impurity control patents (where such claims exist).
- Rapid comparability and stability data for regulatory review.
Supplier risk areas
- API impurity profile mismatch during scale-up.
- Differences in solid-state properties affecting bioequivalence.
- Proprietary process constraints that block certain suppliers from qualifying.
What are the Orange Book status implications for macitentan supply entrants?
Orange Book listings (for the U.S.) determine what has legal relevance for generic entry timing:
- Listed patents tied to drug product, formulation, or method-of-use.
- Exclusivity codes that affect the earliest permitted approval and launch.
Supplier implications
- Entry timing affects whether CMOs and API suppliers enter long-term supply agreements early or wait for generic approvals.
- Patent challenges influence whether supply contracts are structured around launch milestones.
Which biosimilar pathways affect macitentan?
Macitentan is a small-molecule endothelin receptor antagonist, not a biologic. Biosimilar pathways do not apply.
What formulations are protected for macitentan tablets and how does that affect suppliers?
Generic tablet suppliers must address potential formulation patent coverage that can include:
- Specific excipient systems or tablet compositions
- Film coating composition and process parameters
- Particle size targets, solubility modifiers, or stability-enhancing components
Formulation-patent impact
- Limits which CMO formulations can be used without licensing.
- Raises qualification burden for API-to-formulation matching.
How strong is the macitentan patent estate for supply chain licensing?
The strength and coverage of macitentan patents typically drives:
- Whether generic tablets require a license for certain formulation or process claims.
- Whether authorized generics source from brand-linked supply chains or independently qualified suppliers.
What this means for suppliers
- If patents cover critical manufacturing steps or impurity limits, suppliers must engineer around claims or obtain licensing.
- Supply agreements often include IP indemnities and scope limitations.
How does macitentan compare with other endothelin receptor antagonists for supplier concentration?
Macitentan sits in the same therapeutic class as endothelin receptor antagonists such as bosentan and ambrisentan. Supplier concentration patterns differ by:
- Market size and launch timing
- Patent coverage intensity
- Extent of generic penetration
Supplier pattern expectations
- Higher patent density generally correlates with fewer qualified tablet suppliers early.
- Once multiple ANDA approvals exist, API and CMO competition increases and margins compress.
What manufacturing and IP barriers block macitentan API and tablet suppliers?
Key barriers include:
- Solid-state control (crystal form, stability)
- Impurity management, including limits on process-related impurities
- Patent-protected synthetic routes or impurity-bearing intermediates
- DMF constraints in jurisdictions where filings require cross-referencing or bridging
Contractual and compliance barriers
- QA agreements, audit readiness, and batch release traceability.
- Regulatory quality system equivalency for API and finished-dose supply.
Key Takeaways
- Macitentan supply is structured around a small, qualified set of API and tablet manufacturing sites, with supplier participation constrained by patent and regulatory timelines.
- Generic and authorized-entry supply chains increase only after relevant exclusivity and patent challenges clear.
- Supplier qualification for macitentan hinges on solid-state control, impurity profile match, and validated tablet manufacturing processes.
- Biosimilar risk is not applicable; the competitive pressure comes from generics and authorized generics, not biologics.
FAQs
1) Who are the typical contract manufacturers (CMOs) for macitentan tablets?
Macitentan tablet production is generally handled by qualified CMOs under QA disposition and batch release agreements aligned to each market’s authorization holder.
2) Can macitentan API be sourced from multiple suppliers before generic approval?
Supply is usually limited to brand-linked or DMF-supported pathways before generic approvals, because filings and impurity acceptance standards constrain qualification.
3) What matters most in macitentan API impurity control?
Process impurities and degradation products must match regulatory specifications and be stable through shelf-life to support batch release.
4) Do excipients and tablet coating affect macitentan generic bioequivalence risk?
Yes. Formulation composition and manufacturing controls affect dissolution and absorption, which drives BE outcomes and regulatory acceptance.
5) What is the main risk for an API supplier entering macitentan?
Scale-up that shifts impurity profiles or solid-state properties, combined with the need to align manufacturing and documentation to regulatory submissions.
References
- U.S. FDA, Drugs@FDA database.
- U.S. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA guidance documents on ANDA quality and bioequivalence requirements for small-molecule generics.
